The article describes the mechanisms of action, pharmacokinetics, and pharmacodynamics
of aspirin, dipyridamole, cilostazol, the thienopyridines, and the glycoprotein IIb/IIIa …

Dual antiplatelet therapy with aspirin and a thienopyridine has been shown to reduce
cardiac events after coronary stenting. However, many patients and healthcare providers …

AR Naylor a, J.-B. Ricco a, GJ de Borst a, S. Debus a, J. de Haro a, A. Halliday a, G.
Hamilton a, J. Kakisis a, S. Kakkos a, S. Lepidi a, HS Markus a, DJ McCabe a, J. Roy a, H …

In patients with stable CAD, PCI can be considered a valuable initial mode of
revascularization in all patients with objective large ischaemia in the presence of almost …

Background Intravenous cangrelor, a rapid-acting, reversible adenosine diphosphate (ADP)
receptor antagonist, might reduce ischemic events during percutaneous coronary …

This article discusses platelet active drugs as part of the Seventh American College of Chest
Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based …

Current available data show that about 4% to 30% of patients treated with conventional
doses of clopidogrel do not display adequate antiplatelet response. Clopidogrel resistance …

Dual antiplatelet therapy with aspirin and clopidogrel decreases the rate of stent thrombosis
in patients undergoing percutaneous coronary intervention (PCI). However, despite …

This article about currently available antiplatelet drugs is part of the Antithrombotic and
Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical …

Over the past decade, the platelet has emerged as a pivotal entity in cardiovascular
diseases. Indeed, the'preeminence of the platelet'has spawned a variety of drugs that have …